Rohit Aggarwal

990 posts

Rohit Aggarwal banner
Rohit Aggarwal

Rohit Aggarwal

@docrota

Rheumatologist, research in Myositis & Interstitial lung disease, medical director, Myositis Center, Professor of Medicine, @UPMC @pittrheum

Pittsburgh, PA Katılım Aralık 2013
4K Takip Edilen5.8K Takipçiler
Rohit Aggarwal
Rohit Aggarwal@docrota·
Please join this webinar at 7 pm IST or 8.30 am EST on Sunday Feb 8, 2026 if you want to know the latest in the field of clinical trials in myositis.
Myositis India@Myositis_India

Clinical trials aren’t optional in myositis, they’re the backbone of evidence-based care. Join leading experts to discuss key challenges, barriers, and the way forward. 🗓 8 Feb 2026 | SUNDAY |⏰ 7 PM IST 📲 Register via QR #Myositis #ClinicalTrials #Rheumatology

English
0
4
17
1K
Rohit Aggarwal retweetledi
MCTC myositis
MCTC myositis@MctcMyositis·
1/6📣 MCTC is pleased to announce the award of travel grants to 12 applicants from 7 geographic regions, supporting their participation in #GCOM 🌍✈️
English
1
2
7
590
Rohit Aggarwal
Rohit Aggarwal@docrota·
Sharing our editorial on CTD-ILD in Rheumatology (Oxford). Thanks to Dr. Shiri Keret and Daniel Sullivan for this article. Interstitial lung disease in connective tissue diseases: evolving strategies across the disease spectrum academic.oup.com/rheumatology/a…
English
1
12
52
3.4K
Rohit Aggarwal
Rohit Aggarwal@docrota·
Looking for a Project Manager for MCTC (Remote work position). See job posting below. Exciting work in scientific and global environments for a rare disease organization.
MCTC myositis@MctcMyositis

Exciting opportunity with the MCTC! 🌍 We’re hiring a #Project_Manager to support global #clinical_research in #inflammatory myopathies.📷 Apply with cover letter + CV to :myositis.MCTC@gmail.com by Dec 15, 2025.📷myositisclinicaltrialsconsortium.org📷🚀

English
0
5
8
2.1K
Rohit Aggarwal
Rohit Aggarwal@docrota·
Thanks to Dr. Takahisa Gono and team for reviewing Myositis Specific Antibody (MSA) accuracy among commercial assays. Beware of false -ve and +ve results for MSA esp LineBlot assay. Analytical performance of commercial myositis-specific autoantibody te... sciencedirect.com/science/articl…
English
0
7
20
1.9K
Rohit Aggarwal
Rohit Aggarwal@docrota·
#ACR2025 where Rheumatology science, innovation and joy of meeting mentees and colleagues come together ! Congratulations to my mentees for more than 10 posters and presentations this ACR on #myositis
Rohit Aggarwal tweet mediaRohit Aggarwal tweet mediaRohit Aggarwal tweet mediaRohit Aggarwal tweet media
English
1
2
47
2.4K
Rohit Aggarwal
Rohit Aggarwal@docrota·
Great pleasure to meet Lindsay who beat her dermatomyositis with CAR-T treatment. Great to know she is doing remarkably well off all myositis treatment. We need more such patient champions to share experiences with other patients going for transformative recovery with CAR-T. @bmsnews
Rohit Aggarwal tweet media
English
4
12
107
5.5K
Rohit Aggarwal
Rohit Aggarwal@docrota·
Great news for all ILD patients. Anti-fibrotic and immunosuppressive drug combination will help many CTD-ILD patients. I see an increasing role of Nerandomilast in #myositis #ILD as well.
Dr. John Cush@RheumNow

FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. buff.ly/Jeqq1cd

English
1
15
43
3.3K
Rohit Aggarwal
Rohit Aggarwal@docrota·
Happy World Myositis Day ! Help raise awareness about Myositis and support patients and families. To All Myositis Patients - We are with you. Also kudos to all doctors, researchers and scientists who are working towards new and safer treatments for Myositis!
Myositis India@Myositis_India

✨On #WorldMyositisDay, we celebrate Mr. Naresh Pyapili’s incredible spirit! Despite myositis, with care & treatment he completed the 9 km Tirupati Balaji trek—over 2500 steps! 🏞️ Truly an inspiration. ✨ #MyositisIndia #Inspiration #PatientStories

English
1
3
17
1.7K
Rohit Aggarwal
Rohit Aggarwal@docrota·
Incredible breaking news for all myositis patients and physicians: Brepocitinib, a TYK2/JAK1 inhibitor, showed positive and meaningful primary and all secondary outcome with 30 mg daily oral dose in a phase 3 RCT on Dermatomyositis (VALOR trial). @Roivant globenewswire.com/news-release/2…
English
2
11
34
1.8K

Keşfet

@elonmusknews30 @bmsnews @Roivant @elonmusk @BarackObama @taylorswift13 @cristiano @BillGates